- Undergraduate Education
- B.A St. Louis University (1980)
- Graduate Education
- Ph.D. Washington University, St. Louis (1987)
- Postdoc. Washington University, St. Louis (1987-89)
- Professor. Albert Einstein College of Medicine
- Joined Texas A&M in 1996
Crystallography / Drug Design
My lab uses X-ray crystallography to better understand the relationship between proteins and ligands. Tiny differences in the structure of a molecule can radically change the interaction between a protein and ligand and we are only begining to understand how many factors play a role in this interaction. By manipulating the individual components of a compound it is possible to create a chemical that binds to the protein better than the natural substrate, and prevent the natural reaction from occurring. This is the basis for rational drug design. Our efforts have lead us to collaborations with other labs and scientists in many disciplines as our approach to directed compound design has applications not only in basic research but also in pesticide development, health research and clinical research.
Huang, HL, Krieger, IV, Parai, MK, Gawandi, VB, Sacchettini, JC. Mycobacterium tuberculosis Malate Synthase Structures with Fragments Reveal a Portal for Substrate/Product Exchange. J. Biol. Chem. 2016;291 (53):27421-27432.
Park, Y, Pacitto, A, Bayliss, T, Cleghorn, LA, Wang, Z, Hartman, T et al.. Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis. ACS Infect Dis. 2017;3 (1):18-33.
Palencia, A, Li, X, Bu, W, Choi, W, Ding, CZ, Easom, EE et al.. Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase. Antimicrob. Agents Chemother. 2016;60 (10):6271-80.
Martínez-Hoyos, M, Perez-Herran, E, Gulten, G, Encinas, L, Álvarez-Gómez, D, Alvarez, E et al.. Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor. EBioMedicine. 2016;8 :291-301.
Bhatt, VS, Zeng, D, Krieger, I, Sacchettini, JC, Cho, JH. Binding Mechanism of the N-Terminal SH3 Domain of CrkII and Proline-Rich Motifs in cAbl. Biophys. J. 2016;110 (12):2630-41.
Almeida, D, Ioerger, T, Tyagi, S, Li, SY, Mdluli, K, Andries, K et al.. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2016;60 (8):4590-9.
Guardia, A, Gulten, G, Fernandez, R, Gómez, J, Wang, F, Convery, M et al.. N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity. ChemMedChem. 2016;11 (7):687-701.
Bageshwar, UK, VerPlank, L, Baker, D, Dong, W, Hamsanathan, S, Whitaker, N et al.. High Throughput Screen for Escherichia coli Twin Arginine Translocation (Tat) Inhibitors. PLoS ONE. 2016;11 (2):e0149659.
Cheng, YS, Sacchettini, JC. Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance. Biochemistry. 2016;55 (7):1107-19.
Martinot, AJ, Farrow, M, Bai, L, Layre, E, Cheng, TY, Tsai, JH et al.. Mycobacterial Metabolic Syndrome: LprG and Rv1410 Regulate Triacylglyceride Levels, Growth Rate and Virulence in Mycobacterium tuberculosis. PLoS Pathog. 2016;12 (1):e1005351.